EGFR-Mutant Advanced NSCLC: Global Insights on Testing and Treatment Planning

Join us for this interactive live-stream Webinar featuring expert perspectives on current best practices for the treatment of EGFR-mutant, advanced NSCLC, including discussion of patient cases and the opportunity to text your questions to the experts.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Welcome and Introduction
  • Biomarker Testing for EGFR Mutation Status in NSCLC
  • Therapeutic Planning in EGFR-Mutated NSCLC
  • Putting It All Together: Case Discussions
  • Final Thoughts and Audience Question and Answer Session


Date / Time
Event Details


Edward S. Kim, MD, FACP

Senior Vice President
City of Hope Orange County
Irvine, California

Tetsuya Mitsudomi, MD

Division of Thoracic Surgery
Department of Surgery
Kindai University Faculty of Medicine
Osaka-Sayama, Japan

Luiz Paz-Ares, MD, PhD

Medical Oncology
University Hospital Doce de Octubre
Madrid, Spain

Daniel S.W. Tan, MBBS, MRCP, BSc, FAMS

Senior Consultant/Medical Oncologist
Division of Medical Oncology
National Cancer Centre Singapore
Senior Clinician-Scientist
Genome Institute of Singapore

Goal Statement
The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to plan individualized treatment for patients with EGFR mutation–positive NSCLC.

Target Audience
This program is intended for oncologists, nurses, and other providers who care for patients with NSCLC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Implement best practices and guideline-endorsed molecular testing algorithms in NSCLC, including the use of tissue-based and blood-based biomarker testing for evaluation of EGFR mutation status in newly diagnosed patients and those with acquired resistance following EGFR TKI therapy
  • Compare available efficacy and safety data of systemic EGFR targeted therapies throughout the continuum of EGFR mutation–positive NSCLC from the first-line setting to the second-line setting and beyond (including outcomes by type of EGFR mutation)
  • Plan sequential therapy based on an understanding of the mechanisms of resistance following EGFR TKI treatment, including the incidence of T790M and amplification of MET
  • Identify patients eligible to enroll on important ongoing clinical trials evaluating promising investigational agents and combinations for EGFR mutation–positive NSCLC


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.